Company intelligence / Profile preview

Immune Cell

Chicago, Illinois, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~2
Development stage: Phase 1

Overview

Immune Cell Therapy was a private U.S. biotechnology company focused on cancer immunotherapy. Its lead approach was a personalized DNA-based cancer vaccine using semi-allogeneic fibroblasts transfected with autologous tumor-derived DNA, with an initial clinical focus on non-small cell lung cancer and references to breast cancer. Available sources indicate the company reached Phase 1 clinical testing but did not advance to marketed products or NDA approval. The company appears to have become defunct in 2018 after limited clinical activity.

Therapeutic areas: Oncology
Modalities: VaccineCell therapyDNA vaccine
Industry: Biotech

Drug pipeline

1 asset

ICAR30

Unknown

Beyond the preview

Go deeper on Immune Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune Cell.

Explore the full profile